Microparticles in cancer: A review of recent developments and the potential for clinical application

Seminars in Cell and Developmental Biology

Volumn 40, Issue , 2015, Pages 35-40

  Gong, Joyce ^a   Jaiswal, Ritu ^a   Dalla, Penelope ^a   Luk, Frederick ^a   Bebawy, Mary ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Biomarker; Cancer; Microparticle inhibitors; Microparticles; Multidrug resistance; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CALPASTATIN; FOCAL ADHESION KINASE 2; GELATINASE A; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 503; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PANTETHINE; PANTOTHENIC ACID; ROCK INHIBITOR; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; BODY FLUID; BREAST CANCER; BREAST CANCER CELL LINE; CANCER CELL LINE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; COCULTURE; COLON CANCER; COLON CANCER CELL LINE; DISEASE SURVEILLANCE; DOWN REGULATION; DRUG DELIVERY SYSTEM; ENDOMETRIAL CANCER CELL LINE; EXOSOME; EXTRACELLULAR MATRIX; HEAD AND NECK CARCINOMA; HEAD AND NECK CARCINOMA CELL LINE; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEMBRANE MICROPARTICLE; MEMBRANE VESICLE; MESENCHYMAL STEM CELL; METASTASIS; MYELOID LEUKEMIA CELL LINE; NON SMALL CELL LUNG CANCER; NONHUMAN; OSTEOSARCOMA CELL LINE; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR BIOPSY; UPREGULATION; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NEOPLASMS; PATHOLOGY;

ANIMALS; CELL-DERIVED MICROPARTICLES; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 84929264365     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.03.009     Document Type: Review

References (75)

1. Sun D., Zhuang X., Zhang S., Deng Z.B., Grizzle W., Miller D., et al. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv Drug Deliv Rev 2013, 65:342-347.
2. Hugel B., Martinez M.C., Kunzelmann C., Freyssinet J.M. Membrane microparticles: two sides of the coin. Physiology (Bethesda) 2005, 20:22-27.
3. ELA S., Mager I., Breakefield X.O., Wood M.J. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013, 12:347-357.
4. Montoro-Garcia S., Shantsila E., Marin F., Blann A., Lip G.Y. Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Basic Res Cardiol 2011, 106:911-923.
5. Jaiswal R., Gong J., Sambasivam S., Combes V., Mathys J.M., Davey R., et al. Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J 2012, 26:420-429.
6. Jaiswal R., Luk F., Gong J., Mathys J.M., Grau G.E., Bebawy M. Microparticle conferred microRNA profiles - implications in the transfer and dominance of cancer traits. Mol Cancer 2012, 11:37.
7. Bebawy M., Combes V., Lee E., Jaiswal R., Gong J., Bonhoure A., et al. Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia 2009, 23:1643-1649.
8. Gong J., Jaiswal R., Mathys J.M., Combes V., Grau G.E., Bebawy M. Microparticles and their emerging role in cancer multidrug resistance. Cancer Treat Rev 2012, 38:226-234.
9. Gong J., Luk F., Jaiswal R., George A.M., Grau G.E., Bebawy M. Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance. Eur J Pharmacol 2013, 721:116-125.
10. Lu J.F., Luk F., Gong J., Jaiswal R., Grau G.E., Bebawy M. Microparticles mediate MRP1 intercellular transfer and the re-templating of intrinsic resistance pathways. Pharmacol Res 2013, 76:77-83.
11. Gong J., Luk C.F., Jaiswal R., Bebawy M. Microparticles mediate the intercellular regulation of microRNA-503 and proline-rich tyrosine kinase 2 to alter the migration and invasion capacity of breast cancer cells. Front Oncol 2014, 4:220.
12. Dolo V., D'Ascenzo S., Violini S., Pompucci L., Festuccia C., Ginestra A., et al. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metastasis 1999, 17:131-140.
13. Ginestra A., Miceli D., Dolo V., Romano F.M., Vittorelli M.L. Membrane vesicles in ovarian cancer fluids: a new potential marker. Anticancer Res 1999, 19:3439-3445.
14. Kim C.W., Lee H.M., Lee T.H., Kang C., Kleinman H.K., Gho Y.S. Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res 2002, 62:6312-6317.
15. Wysoczynski M., Ratajczak M.Z. Lung cancer secreted microvesicles: underappreciated modulators of microenvironment in expanding tumors. Int J Cancer 2009, 125:1595-1603.
16. van der Pol E., Boing A.N., Harrison P., Sturk A., Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 2012, 64:676-705.
17. Abid Hussein M.N., Boing A.N., Sturk A., Hau C.M., Nieuwland R. Inhibition of microparticle release triggers endothelial cell apoptosis and detachment. Thromb Haemost 2007, 98:1096-1107.
18. Meckes D.G., Raab-Traub N. Microvesicles and viral infection. J Virol 2011, 85:12844-12854.
19. Abrahams V.M., Straszewski-Chavez S.L., Guller S., Mor G. First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis. Mol Hum Reprod 2004, 10:55-63.
20. Huber V., Fais S., Iero M., Lugini L., Canese P., Squarcina P., et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology 2005, 128:1796-1804.
21. Jaiswal R., Luk F., Dalla P.V., Grau G.E., Bebawy M. Breast cancer-derived microparticles display tissue selectivity in the transfer of resistance proteins to cells. PLoS One 2013, 8:e61515.
22. Li L., Jiang A.C., Dong P., Wang H., Xu W., Xu C. MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol. Ann Surg Oncol 2009, 16:1421-1428.
23. Yang J.M., Xu Z., Wu H., Zhu H., Wu X., Hait W.N. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 2003, 1:420-427.
24. Miletti-Gonzalez K.E., Chen S., Muthukumaran N., Saglimbeni G.N., Wu X., Yang J., et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 2005, 65:6660-6667.
25. Ginestra A., La Placa M.D., Saladino F., Cassara D., Nagase H., Vittorelli M.L. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res 1998, 18:3433-3437.
26. Graves L.E., Ariztia E.V., Navari J.R., Matzel H.J., Stack M.S., Fishman D.A. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 2004, 64:7045-7049.
27. Zhou J., Wang W. Analysis of microRNA expression profiling identifies microRNA-503 regulates metastatic function in hepatocellular cancer cell. J Surg Oncol 2011, 104:278-283.
28. Forrest A.R., Kanamori-Katayama M., Tomaru Y., Lassmann T., Ninomiya N., Takahashi Y., et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 2010, 24:460-466.
29. Roy P., Dasgupta U.B. The microRNA hsa-miR-503 inhibits growth of K562 cell line. Blood Cells Mol Dis 2013, 50:271-272.
30. Sarkar S., Dey B.K., Dutta A. MiR-322/424 and -503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A. Mol Biol Cell 2010, 21:2138-2149.
31. Jiang Q., Feng M.G., Mo Y.Y. Systematic validation of predicted microRNAs for cyclin D1. BMC Cancer 2009, 9:194.
32. Xu Y.Y., Wu H.J., Ma H.D., Xu L.P., Huo Y., Yin L.R. MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1. FEBS J 2013, 280:3768-3779.
33. Zhou R., Gong A.Y., Chen D., Miller R.E., Eischeid A.N., Chen X.M. Histone deacetylases and NF-kB signaling coordinate expression of CX3CL1 in epithelial cells in response to microbial challenge by suppressing miR-424 and miR-503. PLoS One 2013, 8:e65153.
34. Niu J., Shi Y., Tan G., Yang C.H., Fan M., Pfeffer L.M., et al. DNA damage induces NF-kappaB-dependent microRNA-21 up-regulation and promotes breast cancer cell invasion. J Biol Chem 2012, 287:21783-21795.
35. Rucci N., Ricevuto E., Ficorella C., Longo M., Perez M., Di Giacinto C., et al. In vivo bone metastases, osteoclastogenic ability, and phenotypic characterization of human breast cancer cells. Bone 2004, 34:697-709.
36. Yang L., Liu F., Xu Z., Guo N., Zheng X., Sun C. Chemokine receptor 7 via proline-rich tyrosine kinase-2 upregulates the chemotaxis and migration ability of squamous cell carcinoma of the head and neck. Oncol Rep 2012, 28:1659-1664.
37. Cao J., Chen Y., Fu J., Qian Y.W., Ren Y.B., Su B., et al. High expression of proline-rich tyrosine kinase2 is associated with poor survival of hepatocellular carcinoma via regulating phosphatidylinositol 3-kinase/AKT pathway. Ann Surg Oncol 2012, 20:S312-S323.
38. Sun C.K., Man K., Ng K.T., Ho J.W., Lim Z.X., Cheng Q., et al. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation. Carcinogenesis 2008, 29:2096-2105.
39. Iiizumi M., Bandyopadhyay S., Pai S.K., Watabe M., Hirota S., Hosobe S., et al. RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res 2008, 68:7613-7620.
40. Yang Y., Liu L., Zhang Y., Guan H., Wu J., Zhu X., et al. MiR-503 targets PI3K p85 and IKK-beta and suppresses progression of non-small cell lung cancer. Int J Cancer 2014, 135:1531-1542.
41. Zhang Y., Chen X., Lian H., Liu J., Zhou B., Han S., et al. MicroRNA-503 acts as a tumor suppressor in glioblastoma for multiple antitumor effects by targeting IGF-1R. Oncol Rep 2014, 31:1445-1452.
42. Nomura S., Inami N., Kimura Y., Omoto S., Shouzu A., Nishikawa M., et al. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 2007, 21:38-44.
43. Antonyak M.A., Wilson K.F., Cerione R.A. R(h)oads to microvesicles. Small GTPases 2012, 3:219-224.
44. Penet M.F., Abou-Hamdan M., Coltel N., Cornille E., Grau G.E., de Reggi M., et al. Protection against cerebral malaria by the low-molecular-weight thiol pantethine. Proc Natl Acad Sci U S A 2008, 105:1321-1326.
45. Roseblade A., Luk F., Rawling T., Ung A., Grau G.E., Bebawy M. Cell-derived microparticles: new targets in the therapeutic management of disease. J Pharm Pharm Sci 2013, 16:238-253.
46. Roseblade A., Luk F., Ung A., Bebawy M. Targeting microparticle biogenesis: a novel approach to the circumvention of cancer multidrug resistance. Curr Cancer Drug Targets 2015.
47. Yu K.F., Zhang W.Q., Luo L.M., Song P., Li D., Du R., et al. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J Nanomed 2013, 8:2473-2485.
48. Lin C.Y., Javadi M., Belnap D.M., Barrow J., Pitt W.G. Ultrasound sensitive Liposomes containing doxorubicin for drug targeting therapy. Nanomedicine 2013, 10:67-76.
49. Latagliata R., Breccia M., Fazi P., Iacobelli S., Martinelli G., Di Raimondo F., et al. Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. Br J Haematol 2008, 143:681-689.
50. Kaspers G.J., Zimmermann M., Reinhardt D., Gibson B.E., Tamminga R.Y., Aleinikova O., et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol 2013, 31:599-607.
51. Tang K., Zhang Y., Zhang H., Xu P., Liu J., Ma J., et al. Delivery of chemotherapeutic drugs in tumour cell-derived microparticles. Nat Commun 2012, 3:1282.
52. Kooijmans S.A., Vader P., van Dommelen S.M., van Solinge W.W., Schiffelers R.M. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomed 2012, 7:1525-1541.
53. Escudier B., Dorval T., Chaput N., Andre F., Caby M.P., Novault S., et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med 2005, 3:10.
54. Morse M.A., Garst J., Osada T., Khan S., Hobeika A., Clay T.M., et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 2005, 3:9.
55. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011, 29:341-345.
56. Mizrak A., Bolukbasi M.F., Ozdener G.B., Brenner G.J., Madlener S., Erkan E.P., et al. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor growth. Mol Ther 2013, 21:101-108.
57. Zhang Y., Liu D., Chen X., Li J., Li L., Bian Z., et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010, 39:133-144.
58. Akao Y., Iio A., Itoh T., Noguchi S., Itoh Y., Ohtsuki Y., et al. Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol Ther 2011, 19:395-399.
59. Kim H.K., Song K.S., Park Y.S., Kang Y.H., Lee Y.J., Lee K.R., et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003, 39:184-191.
60. Smalley D.M., Sheman N.E., Nelson K., Theodorescu D. Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. J Proteome Res 2008, 7:2088-2096.
61. Zwicker J.I., Liebman H.A., Neuberg D., Lacroix R., Bauer K.A., Furie B.C., et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009, 15:6830-6840.
62. Trappenburg M.C., van Schilfgaarde M., Bredewold E.O., van Aalderen M.C., Spronk H.M., Ten Cate H., et al. Elevated numbers and altered subsets of procoagulant microparticles in breast cancer patients using endocrine therapy. Thromb Res 2011, 127:363-369.
63. Fleitas T., Martinez-Sales V., Vila V., Reganon E., Mesado D., Martin M., et al. Circulating endothelial cells and microparticles as prognostic markers in advanced non-small cell lung cancer. PLoS One 2012, 7:e47365.
64. Reynes G., Vila V., Fleitas T., Reganon E., Font de Mora J., Jorda M., et al. Circulating endothelial cells and procoagulant microparticles in patients with glioblastoma: prognostic value. PLoS One 2013, 8:e69034.
65. Toth B., Liebhardt S., Steinig K., Ditsch N., Rank A., Bauerfeind I., et al. Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost 2008, 100:663-669.
66. Toth B., Nieuwland R., Liebhardt S., Ditsch N., Steinig K., Stieber P., et al. Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res 2008, 28:1107-1112.
67. Liebhardt S., Ditsch N., Nieuwland R., Rank A., Jeschke U., Von Koch F., et al. CEA-, Her2/neu-, BCRP- and Hsp27-positive microparticles in breast cancer patients. Anticancer Res 2010, 30:1707-1712.
68. Thaler J., Ay C., Mackman N., Metz-Schimmerl S., Stift J., Kaider A., et al. Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Invest 2013, 43:277-285.
69. Bharthuar A., Khorana A.A., Hutson A., Wang J.G., Key N.S., Mackman N., et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res 2013, 132:180-184.
70. El Andaloussi S., Lakhal S., Mager I., Wood M.J. Exosomes for targeted siRNA delivery across biological barriers. Adv Drug Deliv Rev 2013, 65:391-397.
71. Capriotti A.L., Caruso G., Cavaliere C., Piovesana S., Samperi R., Lagana A. Proteomic characterization of human platelet-derived microparticles. Anal Chim Acta 2013, 776:57-63.
72. Gyorgy B., Paloczi K., Kovacs A., Barabas E., Beko G., Varnai K., et al. Improved circulating microparticle analysis in acid-citrate dextrose (ACD) anticoagulant tube. Thromb Res 2013, 133:285-292.
73. Chen C.L., Lai Y.F., Tang P., Chien K.Y., Yu J.S., Tsai C.H., et al. Comparative and targeted proteomic analyses of urinary microparticles from bladder cancer and hernia patients. J Proteome Res 2012, 11:5611-5629.
74. Bauer M., Zeitlinger M., Todorut D., Bohmdorfer M., Muller M., Langer O., et al. Pharmacokinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy subjects. Pharmacology 2013, 91:12-19.
75. Cripe L.D., Uno H., Paietta E.M., Litzow M.R., Ketterling R.P., Bennett J.M., et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 2010, 116:4077-4085.